Following on from information provided to NICE by the company in September 2017, the appraisal of Pembrolizumab for treating relapsed metastatic colorectal cancer with high microsatellite instability [ID1071] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1071
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Following on from information provided to NICE by the company in September 2017, the appraisal of Pembrolizumab for treating relapsed metastatic colorectal cancer with high microsatellite instability [ID1071] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 20 December 2017 | Draft scope documents |
| 19 October 2017 | Note added to the project documents |
| 12 September 2017 | Suspended. This appraisal has been suspended following discussions with the company. |
| 22 July 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual